A first in human clinical trial assessing ADMIR
Latest Information Update: 24 Aug 2023
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions
- 18 Oct 2021 New trial record
- 12 Oct 2021 According to Vallon Pharma media release, the company is moving towards filing an IND which will allow the commencement of this human clinical trial in 2022